Analytical Data
-
Gene name
E7
- Application
-
Alternative Names
E7；SIAT7E；Alpha-N-acetylgalactosaminide alpha-2.6-sialyltransferase 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BVH7
-
Expression Region
1-336aa
-
AA Sequence
MKTLMRHGLAVCLALTTMCTSLLLVYSSLGGQKERPPQQQQQQQQQQQQASATGSSQPAAESSTQQRPGVPAGPRPLDGYLGVADHKPLKMHCRDCALVTSSGHLLHSRQGSQIDQTECVIRMNDAPTRGYGRDVGNRTSLRVIAHSSIQRILRNRHDLLNVSQGTVFIFWGPSSYMRRDGKGQVYNNLHLLSQVLPRLKAFMITRHKMLQFDELFKQETGKDRKISNTWLSTGWFTMTIALELCDRINVYGMVPPDFCRDPNHPSVPYHYYEPFGPDECTMYLSHERGRKGSHHRFITEKRVFKNWARTFNIHFFQPDWKPESLAINHPENKPVF
-
Molecular Weight
38.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E7 recombinant protein is derived from the oncogenic human papillomavirus (HPV) type 16, which has been implicated in the development of cervical cancer. Research on the E7 protein has gained significant attention due to its critical role in the disruption of cellular regulatory mechanisms, particularly its ability to interact with tumor suppressor proteins such as pRB (retinoblastoma protein). This interaction leads to uncontrolled cell proliferation and contributes to the malignant transformation of host cells. The study of E7 has been pivotal in understanding HPV's oncogenic processes and has facilitated the development of potential therapeutic strategies, including vaccines and immunotherapies aimed at inducing an immune response against HPV-related cancers. Given that HPV infection is a major etiological factor in cervical cancer and other anogenital malignancies, the characterization of E7 and its mechanisms provides crucial insights into preventing and treating these diseases. Furthermore, the recombinant production of E7 allows for its use in experimental settings, enabling researchers to explore its immunogenic properties and assess its potential in clinical applications. The ongoing exploration of E7 recombinant protein continues to be significant for advancing cancer biology and improving patient outcomes in HPV-associated cancers.
